LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $94.57.

Several brokerages have recently issued reports on LMAT. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Oppenheimer restated an “outperform” rating and issued a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Barrington Research increased their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $96.31 on Friday. LeMaitre Vascular has a fifty-two week low of $56.04 and a fifty-two week high of $109.58. The company has a 50 day moving average price of $98.18 and a 200 day moving average price of $92.23. The stock has a market capitalization of $2.17 billion, a P/E ratio of 52.63, a PEG ratio of 2.19 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company’s quarterly revenue was up 15.6% on a year-over-year basis. During the same period last year, the business posted $0.33 earnings per share. Research analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.79% of the stock is owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. Acadian Asset Management LLC acquired a new position in shares of LeMaitre Vascular in the 2nd quarter valued at $104,000. Oppenheimer Asset Management Inc. boosted its stake in LeMaitre Vascular by 16.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 12,372 shares of the medical instruments supplier’s stock valued at $1,018,000 after acquiring an additional 1,767 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of LeMaitre Vascular by 0.7% during the second quarter. Envestnet Asset Management Inc. now owns 215,841 shares of the medical instruments supplier’s stock worth $17,759,000 after purchasing an additional 1,520 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of LeMaitre Vascular by 3.1% during the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the medical instruments supplier’s stock worth $11,527,000 after purchasing an additional 4,164 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at about $82,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.